Biotron Limited ( (AU:BIT) ) has shared an update.
Biotron Limited has announced the commencement of rights trading on the ASX under the ticker code BITR, following a rights issue announced on 28 February 2025. The rights issue offers shareholders in Australia and New Zealand the opportunity to purchase one new share for every share held at $0.003 per share, with the closing date extended to 25 March 2025. This move is expected to provide Biotron with additional capital to further its drug development programs, potentially enhancing its market position in the pharmaceutical industry.
More about Biotron Limited
Biotron Limited is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical needs. The company is developing BIT225 for HIV-1 and COVID-19 and has promising preclinical programs for HBV and other serious viruses. Biotron also focuses on designing drugs targeting viroporins, a class of virus proteins involved in the life cycle of various viruses, including Coronavirus, Dengue, Ebola, and Zika.
YTD Price Performance: 390.0%
Average Trading Volume: 23,250
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.81M
For an in-depth examination of BIT stock, go to TipRanks’ Stock Analysis page.